



Children's Rights

GRI Standards:

408-1: Child Labor

EXECUTIVE SUMMARY

Sanofi's commitment to respect and promote children's rights is a constituent part of our human rights vision and approach. Its aim is to align with the **Ten Children's Rights and Business Principles**⁽¹⁾ developed by UNICEF in March 2012, together with the United Nations (UN) Global Compact and Save the Children.

This factsheet describes Sanofi's commitments to address each of these ten principles, applicable in all countries where it operates or acts with particular attention to protecting and improving their health and access to health care for all children.

¹ The first comprehensive guidance to companies on how to integrate children's rights into their policies and business processes.

TABLE OF CONTENTS

<i>1. Principle 1: All businesses should meet their responsibility to respect children’s rights and commit to supporting the human rights of children</i>	<i>5</i>
1.1. A COMMITMENT EMBEDDED IN OUR HUMAN RIGHTS STATEMENT AND APPROACH	5
1.2. WHAT ARE CHILDREN’S RIGHTS FOR SANOFI?	5
1.3. RAISING AWARENESS ABOUT THE IMPACT OF HUMAN AND CHILDREN’S RIGHTS ON OUR VALUE CHAIN	5
<i>2. Principle 2: All businesses should contribute to the elimination of child labor, including in all business activities and business relationships</i>	<i>6</i>
2.1. ADOPTION OF A POLICY ON CHILD LABOR	6
2.2. OUR COMMITMENT TO ELIMINATE CHILD LABOR IS ALSO EXPRESSED IN OUR INTERNAL REFERENCE DOCUMENTS	6
2.3. ESTABLISHING GRIEVANCE MECHANISMS	7
2.4. IMPLEMENTING A DUE DILIGENCE PROCESS	7
<i>3. Principle 3: All businesses should provide decent work for young workers, parents and caregivers</i>	<i>7</i>
3.1. PROVIDING OUR EMPLOYEES WITH A DECENT STANDARD OF LIVING	7
3.2. IMPROVING EMPLOYEES’ WORK-LIFE BALANCE	8
ENFANTS DE SANOFI: SUPPORTING OUR EMPLOYEES’ CHILDREN AND FAMILIES	8

4. Principle 4: All businesses should ensure the protection and safety of children in all business activities and facilities
9

4.1. IN OUR BUSINESS ACTIVITIES: PROTECTING CHILDREN PARTICIPATING IN SANOFI’S CLINICAL TRIALS..... 9

4.2. IN OUR FACILITIES: ENSURING THE SAFETY OF YOUNG WORKERS
9

5. Principle 5: All businesses should ensure that products and services are safe and seek to support children’s rights through them..... 9

5.1. A LARGE PORTFOLIO OF MEDICINES COVERING A WIDE RANGE OF PEDIATRIC HEALTH ISSUES 10

5.2. SANOFI PASTEUR VACCINES: IMMUNIZING CHILDREN AGAINST VACCINE-PREVENTABLE DISEASES 11

6. Principle 6: All businesses should use marketing and advertising that respect and support children’s rights12

7. Principle 7: All businesses should respect and support children’s rights in relation to the environment and to land acquisition and use12

8. Principle 8: All businesses should respect and support children’s rights in security arrangements12

9. Principle 9: All businesses should help protect children affected by emergencies.....13

10. *Principle 10: All businesses should reinforce community and government efforts to protect and fulfill children’s rights*.....13

10.1. FIGHTING CHILDHOOD CANCER 14

10.2. RAISING AWARENESS ABOUT DIABETES 14

1. Principle 1: All businesses should meet their responsibility to respect children's rights and commit to supporting the human rights of children

1.1. A COMMITMENT EMBEDDED IN OUR HUMAN RIGHTS STATEMENT AND APPROACH

Sanofi's commitment to respect children's rights is embedded into the business from the top, through the endorsement of Sanofi's human rights statement by the Senior Vice President in charge of Corporate Social Responsibility (CSR).

The statement specifies that as a multinational healthcare company keenly aware of its social responsibility; Sanofi is committed to integrating respect for human rights into all its business operations and public positions. We are convinced that, while states and governments have a duty to protect human rights through adequate laws and policies, businesses also have a role to play, which begins with identifying their own impacts on human rights and taking measures to prevent human rights violations.

Among other relevant international standards, Sanofi is committed to upholding the two emerging international reference frameworks that are the United Nations Guiding Principles on Business and Human Rights and The Children's Rights and Business Principles developed by UNICEF, the United Nations Global Compact and Save the Children.

Sanofi's commitment to respect human rights is the foundation of our CSR approach. It provides Sanofi with an inspirational framework and guide for analysis and action towards continuous improvement in our CSR pillars. In line with the United Nations Guiding Principles, Sanofi pays a particular attention to the rights and needs of, as well as the challenges faced by, groups or populations that may be especially vulnerable, such as children.

1.2. WHAT ARE CHILDREN'S RIGHTS FOR SANOFI?

As a global healthcare leader operating in over 100 countries, the Company brings heightened attention to:

- **human rights at work**, including the right to safe working conditions and the elimination of child labor, whether for Sanofi's employees or those of its suppliers and business partners;
- **the right to health**, and all human rights related to, or constitutive of, this right, such as access to healthcare or the issue of pharmaceuticals in the environment. Children under the age of 18 account for nearly one-third of the global population, and we are committed to protecting and improving their health, and support governments and other stakeholders' efforts to reduce the barriers to access to healthcare for children; and
- **the whole spectrum of human rights of patients and clinical trial participants**, going beyond the right to health to encompass, for instance, the right to access information or the right to privacy.

1.3. RAISING AWARENESS ABOUT THE IMPACT OF HUMAN AND CHILDREN'S RIGHTS ON OUR VALUE CHAIN

Since 2013, the company issued an awareness-raising guide, Human Rights in our Activities, for all its employees.

Built from the results of the participatory self-assessment conducted at company level, the Human Rights in our Activities guide maps Sanofi's potential human rights impacts along the four steps of a drug's lifecycle, with a transverse section on human rights at work, including issues related to child labor.

It was designed with four aims:

- to inform and familiarize all Sanofi employees with the key concepts and principles of respect for human rights;
- to raise awareness about the spectrum of human rights risks related to the functional responsibilities of our personnel and business partners;
- to describe a selection of relevant best practices implemented at Sanofi; and
- to act as a reference point for Sanofi managers making decisions about potential issues linked to human rights in their daily activity.

The Human Rights in our Activities guide is deployed through internal tools such as a slide kit for managers and a dedicated website to help Sanofi managers better understand their role and responsibilities in applying human rights principles.

For more information, see our in the [Document Center](#): the Human Rights in our Activities guide and The Human Rights Due Diligence Factsheet

2. Principle 2: All businesses should contribute to the elimination of child labor, including in all business activities and business relationships

2.1. ADOPTION OF A POLICY ON CHILD LABOR

Since 2015, we have continued our human rights due diligence process in line with the UN guiding principles with a focus on strengthening our internal guidelines on human rights at work.

We therefore integrated human rights in our internal control manual with the implementation of a dedicated control covering child labor and put in place human rights training for the internal auditors covering the Europe, Africa, Middle East and South Asia regions.

In order to ensure a common understanding of this control across the company, a new global policy on Child Labor Policy was released in 2015.

According to this new Child Labor Policy, Sanofi commits to respect at a minimum the provisions of the International Labour Organization (ILO) conventions 138 and 182 on the prohibition of child labor, without prejudice to more favorable national provisions. It rejects all forms of child labor as defined by these international labor standards and requires its suppliers to comply with the same standards.

This means that:

- (1) Sanofi is not engaged in and does not support any form of child labor;
- (2) employment of persons under the age of 15 or under the legal age for finishing compulsory schooling is prohibited; and
- (3) no hazardous work can be performed by a person under the age of 18.

This global policy applies to all Sanofi corporate functions, regions, countries and divisions worldwide. Specific measures must be defined to implement this policy in the supply chain.

For more information, see our [Document Center](#): Fundamental Human Rights at Work Factsheet.

2.2. OUR COMMITMENT TO ELIMINATE CHILD LABOR IS ALSO EXPRESSED IN OUR INTERNAL REFERENCE DOCUMENTS

The human rights principles and Sanofi's commitments, including those applicable to children, which Sanofi upholds, are also listed in our key internal reference documents, such as:

- the Social Charter;
- the Code of Conduct; and

- the Suppliers' Code of Conduct.

These documents present human rights as a core element of Sanofi's company values and contribute to embedding human and children's rights in our company culture. The Sanofi Social Charter, for instance, sets out employees' fundamental rights in accordance with the relevant ILO conventions related to child labor:

- C138: Minimum Age Convention, 1973; and
- C182: Worst Forms of Child Labour Convention, 1999.

They also set forth our expectations towards our stakeholders to meet their responsibility to respect human rights — explicitly stating that the mentioned criteria are to be considered as the minimum applicable standard should local regulations be less stringent in any of Sanofi's countries of operation.

In addition, Sanofi's Suppliers' Code of Conduct stipulates that:

- the minimum working age must never be less than 15 years of age, regardless of the type of activity; and
- the minimum age of employment for labor which, due to its nature or to the conditions in which it is exercised, may jeopardize the health, safety or morality of children or teenagers, must never be less than 18 years of age.

Every employee must therefore be aware of and commit to individually respect principles of the reference documents upheld by Sanofi, both internally and externally.

For more information, see our [Document Center](#): Code of Conduct, Suppliers Code of Conduct, Social Charter.

2.3. ESTABLISHING GRIEVANCE MECHANISMS

As described in the Code of Conduct, any employee must inform his or her superior or the Ethics & Business Integrity Department representative of any case or suspected case of child labor.

2.4. IMPLEMENTING A DUE DILIGENCE PROCESS

Sanofi implements a global "child labor" due diligence process:

- at every level of the Company, vigilance must be reinforced to ensure appropriate mitigation of the risk of use or benefit from child labor;
- adequate internal control measures must be in place to ensure no use of child labor; and
- the Procurement Risk Management Model must identify and assess suppliers according to their respect of the prohibition of child labor.

3. Principle 3: All businesses should provide decent work for young workers, parents and caregivers

3.1. PROVIDING OUR EMPLOYEES WITH A DECENT STANDARD OF LIVING

Sanofi's compensation policy aims at providing wages that are sufficient to cover employees' basic needs (food, children's education, family expenditure on goods and services, etc.), thus contributing indirectly to the avoidance of child labor, often used as a complementary resort to compensate family revenue.

Sanofi also seeks to provide all employees worldwide with high-quality benefits covering health, pension, incapacity, disability, and death. In all countries, employees (as well as, in general, their spouses and children) receive reasonable reimbursements of medical expenses, as well as death benefits.

For more information, see our [Publications](#): section 4.3.1.4.1.2. High quality employee benefits, in the Declaration of Extra-Financial Performance.

3.2. IMPROVING EMPLOYEES' WORK-LIFE BALANCE

Sanofi is committed to improving the work-life balance of its employees, including those who are parents. We are aware of the challenge of managing work accountabilities and career aspirations while handling parenthood and associated responsibilities. In line with our D&I strategy, we are rolling out a global standard for inclusive and equal parental leave. From January 1, 2022, Sanofi will grant 14 weeks paid parental leave to any Sanofi employee welcoming a new child through childbirth or adoption, no matter which country they are working in and irrespective of gender or sexual orientation, as long as the employee is recognized as the child's parent as per local legislation or practice.

Since pioneering this policy in Latin America in 2020, we have seen first-hand the concrete and positive impact it can have for employees becoming parents. It will give our employees the freedom to determine the childcare arrangements that work best for them as a family and provide quality time to better bond together: a step forward for driving equality in the workplace and greater choices beyond.

As part of the new D&I strategy, Sanofi's "Global Flexible Work guidelines" have been updated based on a consistent global framework launched in May 2021. The global guidelines are applied locally through country-wide policies defined and implemented by Sanofi's local country teams in full compliance with local labor law and practices.

By 2025, Sanofi is committed to offering access to flexible working arrangements to 100% of employees, subject to their job profile.

For more information, our [Document Center](#): Diversity and Inclusion factsheet; and see our [Publications](#): section 4.3.1.5. Creating our Diversity Edge, in the Declaration of Extra-Financial Performance.

ENFANTS DE SANOFI: SUPPORTING OUR EMPLOYEES' CHILDREN AND FAMILIES

Sanofi is committed to helping employees' children up to the age of 25 who are experiencing difficulties as a result of medical problems, educational difficulties, or social and family troubles.

Sanofi's *Enfants de Sanofi* program is an association under French law (charitable organization) that provides individual support to our employees' families worldwide by responding to individual requests, and also takes collective actions in many subsidiaries like vaccination, dental care, and eyesight test campaigns and educational programs.

In 2021, *Enfants de Sanofi* supported 144 employees' children in 32 countries, and organized collective actions in 14 countries for 3 000 children such as:

- vaccinations in Egypt, the Philippines and Vietnam;
- medical checkups in China;
- sight tests in Hungary;

For more information, see [Enfants de Sanofi, Rapport Annuel 2021](#).

4. Principle 4: All businesses should ensure the protection and safety of children in all business activities and facilities

4.1. IN OUR BUSINESS ACTIVITIES: PROTECTING CHILDREN PARTICIPATING IN SANOFI'S CLINICAL TRIALS

We are committed to conducting exemplary clinical trials worldwide by applying the most stringent quality standards. Our responsibility is also to ensure that all participants in clinical trial programs have provided genuine, individual, informed consent.

More specifically, we make a particular effort to ensure that children's fundamental rights, such as the right to information on the benefits and risks prior to giving consent, are respected and protected. We engage in different kinds of actions:

- Sanofi provides specific texts to children that explain the rules of informed consent in a simple and understandable way.
- Sanofi has set up specific tools tailored to children, such as adapted pain scales.

For example, Sanofi France produced a film for people who are considering taking part in a clinical trial, including in pediatric clinical trials, which explains the rules of informed consent, gives trial-related information, and describes the documents that must be delivered to patients, the restrictions, and the importance of taking one's time to decide.

4.2. IN OUR FACILITIES: ENSURING THE SAFETY OF YOUNG WORKERS

Through its health and safety policy, Sanofi deploys actions and measures to safeguard the physical and mental health of all employees, including young workers as permitted by Sanofi's internal reference documents, by minimizing their exposure to chemical, biological and physical factors, and by taking measures to ensure their well-being at work.

As described above, the Suppliers' Code of Conduct, which refers among other instruments to the ILO conventions on child labor, sets out the standards we expect our suppliers to comply with in order to fight against child labor and protect workers' health and safety. The minimum age for employment is set at 15 years; workers under the age of 18 shall not perform tasks that are likely to jeopardize their health, safety or morality.

For more information, our [Document Center](#): *Health and Safety in the Workplace factsheet*; and see our [Publications](#): 4.3.14. *Procurement and subcontracting, in the Declaration of Extra-Financial Performance*.

5. Principle 5: All businesses should ensure that products and services are safe and seek to support children's rights through them

Finding innovative solutions to improve access to quality healthcare, including to essential medicines and vaccines, is an everyday objective for Sanofi.

Sanofi pays particular attention to the rights and needs of, as well as the challenges faced by, children.

5.1. A LARGE PORTFOLIO OF MEDICINES COVERING A WIDE RANGE OF PEDIATRIC HEALTH ISSUES

Today, Sanofi's portfolio covers a large part of the molecules and vaccines in the World Health Organization's (WHO) list of essential medicines for children:

- prevention (pediatric, meningococcal and rabies vaccination);
- acute infections (respiratory, gastrointestinal and urinary infections; typhoid fever; meningitis; pain and fever);
- endemic disease (malaria, tuberculosis, sleeping sickness, leishmaniasis);
- chronic disease (epilepsy, diabetes, allergies); and
- genetic disease (rare diseases).

We provide medication and healthcare tools to address numerous fundamental childhood health issues, from the routine to the life-threatening, offering major therapeutic solutions in many areas of pediatrics, such as: pain and fever; gastrointestinal disorders and parasitology; allergic and respiratory diseases; epilepsy, diabetes and vaccine-preventable diseases.

Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

RSV is the most common cause of lower respiratory tract infections (LRTI), including bronchiolitis and pneumonia in infants.⁽²⁾ It is also a leading cause of hospitalization in all infants, with most hospitalizations for RSV occurring in healthy infants born at term.⁽³⁾ Globally, in 2019, there were approximately 33 million cases of acute lower respiratory infections leading to more than three million hospitalizations, and it was estimated that there were 26,300 in-hospital deaths of children younger than five years.⁽⁴⁾

Nirsevimab, a long-acting antibody designed for all infants for protection against RSV disease from birth through their first RSV season with a single dose, is being developed jointly by Sanofi and AstraZeneca. Nirsevimab has been developed to offer newborns and infants direct RSV protection via an antibody to help prevent medically attended lower respiratory tract infections caused by RSV. Monoclonal antibodies do not require the activation of the immune system to help offer timely, rapid and direct protection against the disease.⁵ New data from the HARMONIE Phase 3b clinical trial show an 83.21% (95% CI 67.77 to 92.04; P<0.001) reduction in hospitalizations due to RSV-related LRTD in infants under 12 months of age who received a single dose of nirsevimab, compared to infants who received no RSV intervention.⁶

The Hospitalized RSV Monoclonal Antibody Prevention (HARMONIE) study is a large, multi-country European interventional clinical trial aiming to determine the efficacy and safety of a single intramuscular dose of nirsevimab, with data collected in a real-world setting during the 2022-2023 RSV season⁷ The trial recruited more than 8,000 infants and took place at nearly 250 sites across France, Germany and the

² R K. Respiratory Syncytial Virus Vaccines. Plotkin SA, Orenstein WA, Offitt PA, Edwards KM, eds Plotkin's Vaccines 7th ed Philadelphia. 2018;7th ed. Philadelphia:943-9.

³ Leader S, Kohlhasse K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. The Pediatric infectious disease journal. 2002;21(7):629-32.

⁴ Shi T, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017;390:946-58.

⁵ Centers for Disease Control and Prevention. Vaccines & Immunizations. August 18, 2017. <https://www.cdc.gov/vaccines/vac-gen/immunity-types.htm>. Accessed May 2023.

⁶ Smith DK, et al. Respiratory Syncytial Virus Bronchiolitis in Children. *Am Fam Physician*. 2017;95(2):94-99.

⁷ Drysdale S, et al. Efficacy of nirsevimab against RSV lower respiratory tract infection hospitalization in infants: preliminary data from the HARMONIE phase 3b trial. Presented at 41st Annual Meeting of the European Society for Paediatric Infectious Diseases in Lisbon, 2023.

United Kingdom. The data from HARMONIE were presented at the 41st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID).

Nirsevimab has been granted marketing authorization in the European Union, the United Kingdom, and Canada for the prevention of RSV lower respiratory tract disease in newborns and infants from birth through their first RSV season and is currently undergoing regulatory review in the U.S. In Canada, Beyfortus is also approved for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

For more information, see the [Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting](#)

5.2. SANOFI PASTEUR VACCINES: IMMUNIZING CHILDREN AGAINST VACCINE-PREVENTABLE DISEASES

More than 22 million children worldwide (one child out of five, mostly in low-income countries) currently do not have access to even the most basic package of childhood vaccines⁽⁸⁾. At the same time, in other parts of the world, including high-income countries, the benefit of vaccination is becoming less obvious to some populations. Because of lower vaccination coverage, we see the resurgence of diseases that had almost disappeared, such as measles or pertussis.

Access to vaccination is hampered by multiple barriers that may be structural (e.g., health systems, conflicts, affordability, etc.) or societal (behaviors, education, beliefs). This multifactorial challenge can only be addressed by committed partnerships between all the actors with a stake in the sustained success of vaccination and prevention programs.

True to our vision of a world where no one suffers or dies from a vaccine-preventable disease, Sanofi Pasteur is committed to working on multiple levels to optimize the impact of vaccination:

- developing a broad portfolio of vaccines and solutions to address worldwide epidemiological challenges;
- playing an active role in key public-private partnerships;
- providing effective and affordable vaccines and protection to all populations, regardless of their level of wealth; and
- contributing to local capacity building of healthcare systems to prevent infectious diseases.

Polio eradication is in sight



Polio is a contagious disease that mainly affects children under five. One in 200 infections leads to irreversible paralysis. Over the last 30 years, under the Global Polio Eradication Initiative (GPEI), 2.5 billion children have been immunized against polio resulting in a 99% reduction in the number of cases worldwide. At the end of 2022, polio was endemic in only two countries (Afghanistan and Pakistan) with 30 wild polio virus cases reported (compared with six in 2021). As a result of the global effort to eradicate the disease, almost 20 million people have been saved from paralysis.

⁸ GAVI Alliance Library & News, Mid-term review, October 30, 2013. https://www.gavi.org/sites/default/files/document/2019/GAVI_MTR%202013_En.pdf

The polio strategy aims for all polio viruses to have been sustainably eradicated worldwide – meaning no cases have been detected for three years – by 2026.⁴ Since 1988, Sanofi has been a key partner of the Global Polio Eradication Initiative and has supplied more than 14 billion doses of Oral Polio Vaccine (OPV) and 1.5 billion doses of Inactivated Polio Vaccine (IPV) in the world. In 2022, Sanofi supplied a total of 47 million doses of IPV vaccine to UNICEF for GAVI countries. In addition, 32 million doses of polio vaccine were provided to Brazil, India, Indonesia and the Philippines.

Sanofi has expanded its IPV production capacities and is in a position to contribute greatly to the demand of doses needed for this unprecedented global rollout of polio vaccination. Between 2014 and 2022, Sanofi supplied 395 million IPV doses to UNICEF.

6. Principle 6: All businesses should use marketing and advertising that respect and support children’s rights

Sanofi is committed to ethical marketing practices through:

- the adherence to the codes governing our industry in Europe (EFPIA), the United States (PhRMA) and worldwide (IFPMA); and
- our own internal codes governing our promotional activities.

Our overarching concern is ensuring patient safety and the proper use of our products. In the marketing of our products, including drugs available without a prescription, we are committed to provide accurate, complete and reliable information to physicians, pharmacists and other healthcare professionals. All our promotional materials are based on scientifically proven results and undergo an internal (by the Global Quality Direction) and external (by health authorities) review process, in order to ensure that the information provided is objective and fair.

7. Principle 7: All businesses should respect and support children’s rights in relation to the environment and to land acquisition and use

To safeguard the health of communities and of children everywhere, we continually seek to limit the environmental impact of our activities along the entire life cycle of our products, from development through marketing, and monitoring pharmaceuticals in the environment.

Because Sanofi believes that reducing greenhouse gas emissions and using energy responsibly are part of our mission to help protect life on the planet, we are committed to optimizing our energy consumption and energy security, and reducing our carbon footprint. We are also committed to managing water responsibly in the interest of future generations and their continued access to the resource.

Pharmaceuticals found in the environment due to human activity — such as patients’ disposal of medicines or effluents from drug production facilities — are the focus of growing attention. Even in trace amounts, their presence represents a potential health concern for adults and children alike, and this is a challenge that Sanofi takes seriously. Sanofi addresses this challenge through a multifaceted program ranging from supporting take back programs of unused medicines to implementing cutting-edge technologies to reduce discharge from our chemical and pharmaceutical sites in India, for example.

8. Principle 8: All businesses should respect and support children’s rights in security arrangements

Sanofi does not use public forces to ensure the security of its premises.

When necessary, Sanofi hires private security forces, and ensures that their behavior is in line with Sanofi's security policy, which includes respect for children's rights.

9. Principle 9: All businesses should help protect children affected by emergencies

Through Foundation S – the Sanofi Collective, our new philanthropic organization launched in 2022 – we support vulnerable communities around the world by focusing on children and families impacted by childhood cancer; helping communities in low- and middle-income countries (LMICs) adapt and build resilience to the effects of climate change; supporting the global ambition of eliminating sleeping sickness by 2030; and helping displaced populations during times of humanitarian crises with financial aid and medicine donations.

Foundation S provides humanitarian aid to communities and displaced populations during times of emergency and crises. Through multiple partnerships such as with TULIPE, Foundation S provides medicine donations to countries around the world. In 2022, TULIPE donations included Sri Lanka, Nigeria, Chad and the Democratic Republic of Congo. In total in 2022, Foundation S donated essential medicines equivalent to 45 million daily treatments to treat 22 million patients. The value of these donated products was approximately €26 million.

Donations in 2022 included:

Ukraine: Through the Red Cross, Foundation S donated medicines and vaccines to support Ukrainian patients and refugees:

- 37 million daily treatments (21 million people treated) for diabetes, cardiovascular disease, epilepsy, and other life-threatening and chronic conditions, as well as 450,000 vaccines (300,000 diphtheria and tetanus doses, and 150,000 flu doses).
- Financial contribution of €4 million to the Red Cross to support people in Ukraine and neighboring countries, and €1 million to UNHCR to assist refugees.
- Matching of employee donations (2,800 employees) to Ukraine, which reached €700,000.

Pakistan: Through UNICEF and the Red Cross, Foundation S provided support to people and communities displaced and impacted by the unprecedented floods in Pakistan. The donation included:

- €600,000 in cash and 3.9 million daily treatments of antibiotics, reaching approximately 560,000 people treated.

Lebanon: Through TULIPE, the Lebanese Ministry of Health, and the Centre de Crise et de Soutien (CCDS) of the French Foreign Affairs Ministry, Foundation S was able to mobilize aid to support people during a cholera outbreak. The donation included:

- 13,500 cholera vaccines, reaching 13,500 people.

10. Principle 10: All businesses should reinforce community and government efforts to protect and fulfill children's rights

Sanofi participates in numerous projects, in close cooperation with local governments and institutions, to protect and fulfill children's right to health and education.

10.1. FIGHTING CHILDHOOD CANCER

Worldwide, nearly 400,000 cases of cancer are diagnosed in children under the age of 19 every year. Nearly 80% of them live in countries with limited resources where survival rates are as low as 20% to 30%, while in the US and other developed nations 80% of children with cancer survive.² The 'My Child Matters' program (MCM) was launched in 2005 to increase childhood cancer survival rates by providing financial support to families and children living with cancer. The program aims to strengthen healthcare systems in LMICs by improving their ability to diagnose and treat childhood cancers. The program focuses on training healthcare professionals, improving data collection through cancer registries, raising public awareness, improving the quality and speed of diagnosis, ensuring treatment continuation and adherence, and improving access to and the delivery of pain relief and palliative care. MCM is a collaboration between partners such as the Groupe Franco-Africain d'Oncologie Pédiatrique (GFAOP), the International Society of Pediatric Oncology (SIOP), numerous non-governmental organizations (NGOs), and healthcare experts from hospitals across the world. Since 2005, My Child Matters has provided support to 51 hospitals and NGOs in 33 countries, helping more than 140,000 children, and training over 40,000 healthcare professionals. The program has been credited with considerably increasing survival outcomes.

To foster best-practice sharing between experts and countries, the MCM program launched an open data platform in 2022. The aim is to highlight all MCM programs globally and to ensure all stakeholders fighting childhood cancer can benefit from critical data, know-how and the most recent scientific publications in pediatric oncology.

Cancer remains the leading cause of death from disease in children in the developed world. Most of the medicines we use to treat children today – with some exceptions – were approved in the 1950s, 1960s and 1970s. Today, there is no established business model for developing innovative treatments for childhood cancers, as they are a constellation of rare and ultra-rare diseases. Also, a perception exists that there are regulatory hurdles to studying new drugs in children. As a result, progress in new therapeutic development has been limited despite regulatory requirements and incentives.

As part of its CSR strategy, Sanofi has set itself the ambition to develop innovative treatments to eliminate cancer deaths in children. To achieve this, Sanofi will leverage its R&D capabilities to develop highly effective, less toxic novel therapeutics for children with cancer. In addition, the median time between the first-in-human adult trial and first-in-child clinical trial is currently 6.5 years. Sanofi aims to reduce delays in launching clinical trials for children with cancers to less than 3 years relative to adult trials. The company is looking at compounds at very early stages of development – ideally before entering human trials – to consider what additional laboratory data is needed, and be ready to initiate pediatric clinical trials on a timely basis.

Collaboration with the pediatric cancer community will continue to be central to meeting current challenges. In 2021 and 2022, Sanofi established collaborations with the Innovative Therapies for Children with Cancer's Pediatric Preclinical Proof of Concept Platform (ITCCP4) and Convening Experts in Oncology to Address Children's Health (COACH). In addition, Sanofi is working with experts at institutions and other childhood cancer research networks – including the Children's Oncology Group, MD Anderson Cancer Center, Institut Gustave Roussy, Memorial Sloan Kettering Cancer Center, and Children's Hospital of Philadelphia – to help prioritize pipeline drugs for development based on emerging data and unmet patient need. Sanofi is continuing to conduct additional pre-clinical evaluations to support prioritization and is preparing for the first clinical trial under this initiative, with an estimated launch in 2024.

10.2. RAISING AWARENESS ABOUT DIABETES

In 2021, the International Diabetes Federation estimated that 537 million adults and 1.2 million children were living with diabetes. Rising rates of obesity and reduced physical exercise mean that type 2 diabetes is affecting people at ever younger ages, making it a global public health issue with serious consequences. Since 2021, the new WHO Global Compact to speed up action to tackle diabetes called on nation states to expand education at community level to improve understanding of diabetes, and of how it can be prevented and treated.

School plays an important role in supporting these children, but for many of them, a lack of knowledge about diabetes within schools can lead to feelings of isolation, stigmatization and discrimination.

Kids and Diabetes in Schools (KiDS), a far-reaching educational project initiated in 2013 by the International Diabetes Federation (IDF), the International Society for Pediatric and Adolescent Diabetes (ISPAD) and Sanofi, aims to bring diabetes education to schools to fight diabetes-related stigma and promote healthy lifestyles to tackle the preventable risk factors for type 2 diabetes. The KiDS project operates in each country through partnerships with various parties, such as governmental authorities, patient groups, learned societies and NGOs.

Sanofi's partners organize briefings and schools-based activities, based on core messages delivered through educational material comprising information and awareness packs for teachers and school staff, and for schoolchildren aged 6-14 and their parents; these include a guide to nutrition and diabetes, and the NutriQuiz online game. This material is culturally adapted and translated for the target audience. The KiDS program also encourages local and national decision-makers to pursue local policy changes regarding the management of type 1 diabetes and prevention strategies for type 2 diabetes in children.

In 2022, the KiDS program reached 103,450 children and more than 1500 teachers across seven countries. In addition, a total of 136 new schools were included in the program in 2022 and three countries, Argentina, Algeria and Hungary, participated for the first year. Since inception, KiDS has been implemented in more than 2,200 schools across ten countries, with more than 443,450 children reached and 21,300 teachers and school staff trained.

In Goa (where one of Sanofi's manufacturing sites is located), Sanofi India has partnered with the Department of Health and Education, Government of Goa, along with its' implementing partner Conexus, to run the KiDS program since 2019. To make the program sustainable, we have trained 77 doctors attached to government schools from the State Government's team, who are trained to recognize Type 1 diabetes and to treat NCDs. We have also conducted engaging programs to promote adoption of a healthier lifestyle (STEP program, under which a child and adult compete to complete 10,000 steps a day, and Sakhar Free Shukrawar (Hindi for Sugar Free Fridays), a unique cooking competition where children substitute sugar for healthier options). The partnership has been extended for 3 more years until the beginning of 2025.